ReviewThe oncologist2022

Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies.

Laith Al-Showbaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.